

BIOCON GROUP

FACT SHEET

December - 2017

BIOCON LIMITED (CONSOLIDATED)		
BALANCE SHEET		
	(Rs Cr)	
	December 31, 2017	March 31, 2017
ASSETS		
Non-current assets		
(a) Property, plant and equipment	3,498	3,553
(b) Capital work-in-progress	711	533
(c) Investment property	1	1
(d) Goodwill	26	26
(e) Other intangible assets	43	46
(f) Intangible assets under development	424	306
(g) Investments in associates and a joint venture	58	42
(h) Financial assets	-	-
Investments	-	146
Derivative assets	142	109
Other financial assets	24	20
(i) Income-tax asset, net	115	90
(j) Deferred tax asset, net	189	197
(k) Other non-current assets	361	278
	5,592	5,347
Current assets		
(a) Inventories	736	635
(b) Financial assets		
Investments	1,234	1,065
Trade receivables	1,015	883
Cash and cash equivalents	362	710
Other bank balances	205	334
Derivative assets	126	106
Other financial assets	197	155
(c) Other current assets	160	159
	4,035	4,047
TOTAL	9,627	9,394
EQUITY AND LIABILITIES		
Equity		
(a) Share capital	300	100
(b) Other equity	4,763	4,738
Equity attributable to equity holders of the Company	5,063	4,838
Non-controlling interest	452	376
	5,515	5,214
Non-current liabilities		
(a) Financial liabilities		
Borrowings	1,915	2,108
Derivative liability	7	6
Other financial liabilities	-	-
(b) Provisions	41	36
(c) Other non-current liabilities	333	352
	2,296	2,502
Current liabilities		
(a) Financial liabilities		
Borrowings	207	97
Trade payables	963	740
Derivative liability	2	6
Other financial liabilities	396	326
(b) Short-term provision	56	47
(c) Income tax liability, net	95	96
(d) Other current liabilities	97	366
	1,816	1,678
TOTAL	9,627	9,394

BIOCON LIMITED (CONSOLIDATED)			(Rs. Crores)
PROFIT & LOSS STATEMENT			
Particulars	9M FY 18	9M FY 17	Variance
INCOME			
Small molecules	1,082	1,246	-13%
Biologics	529	539	-2%
Branded formulations	462	418	11%
Research services	1,014	910	11%
Inter-segment	(127)	(122)	5%
Revenue from operations #	2,960	2,991	-1%
Other income	139	126	9%
TOTAL REVENUE	3,099	3,117	-1%
EXPENDITURE			
Material & Power costs	1,302	1,228	6%
Staff costs	612	509	20%
Research & Development expenses*	165	201	-18%
Other expenses	285	273	4%
Manufacturing, staff & other expenses	2,364	2,211	7%
EBITDA	735	906	-19%
Interest & Finance charges	44	21	112%
Depreciation & Amortisation	290	205	42%
Share of profit in JV	(16)	(11)	50%
PBT BEFORE EXCEPTIONAL ITEM	417	691	-40%
Exceptional item, Net	-	-	-
PBT	417	691	-40%
Taxes	117	151	-23%
NET PROFIT BEFORE MINORITY INTEREST	300	540	-44%
Minority interest	58	55	6%
NET PROFIT FOR THE PERIOD	242	485	-50%
EPS Rs.	4.0	8.1	
<i>Note: The figures are rounded off to the nearest crores, percentages are based on absolute numbers</i>			
# Licensing Income	21	129	
* Gross Research & Development expenses	283	304	

BIOCON LIMITED (CONSOLIDATED)			(Rs. Crores)
PROFIT & LOSS STATEMENT			
Particulars	Q3 FY 18	Q3 FY 17	Variance
INCOME			
Small molecules	369	407	-9%
Biologics	190	222	-15%
Branded formulations	156	123	27%
Research services	388	332	17%
Inter-segment	(45)	(40)	10%
Revenue from operations #	1,058	1,044	1%
Other income	34	48	-28%
TOTAL REVENUE	1,092	1,092	0%
EXPENDITURE			
Material & Power costs	469	407	15%
Staff costs	215	179	19%
Research & Development expenses*	53	85	-37%
Other expenses	99	97	2%
Manufacturing, staff & other expenses	836	768	9%
EBITDA	256	324	-21%
Interest & Finance charges	15	9	67%
Depreciation & Amortisation	97	71	39%
Share of profit in JV	(6)	(1)	675%
PBT BEFORE EXCEPTIONAL ITEM	150	245	-39%
Exceptional item, Net	-	-	-
PBT	150	245	-39%
Taxes	36	54	-34%
NET PROFIT BEFORE MINORITY INTEREST	114	191	-40%
Minority interest	22	20	11%
NET PROFIT FOR THE PERIOD	92	171	-46%
EPS Rs.	1.5	2.9	
<i>Note: The figures are rounded off to the nearest crores, percentages are based on absolute numbers</i>			
# Licensing Income	12	79	
* Gross Research & Development expenses	94	100	

BIOCON LIMITED (CONSOLIDATED)			(Rs. Crores)
PROFIT & LOSS STATEMENT			
Particulars	Q3 FY 18	Q2 FY 18	Variance
INCOME			
Small molecules	369	351	5%
Biologics	190	156	22%
Branded formulations	156	176	-11%
Research services	388	335	16%
Inter-segment	(45)	(49)	-9%
Revenue from operations #	1,058	969	9%
Other income	34	50	-33%
TOTAL REVENUE	1,092	1,019	7%
EXPENDITURE			
Material & Power costs	469	423	11%
Staff costs	215	204	5%
Research & Development expenses*	53	54	-2%
Other expenses	99	105	-6%
Manufacturing, staff & other expenses	836	786	6%
EBITDA	256	233	10%
Interest & Finance charges	15	13	7%
Depreciation & Amortisation	97	94	4%
Share of profit in JV	(6)	(6)	5%
PBT BEFORE EXCEPTIONAL ITEM	150	132	14%
Exceptional item, Net	-	-	-
PBT	150	132	14%
Taxes	36	43	-15%
NET PROFIT BEFORE MINORITY INTEREST	114	89	28%
Minority interest	22	20	7%
NET PROFIT FOR THE PERIOD	92	69	33%
EPS Rs.	1.5	1.1	
<i>Note: The figures are rounded off to the nearest crores, percentages are based on absolute numbers</i>			
# Licensing Income	12	1	
* Gross Research & Development expenses	94	93	